Article
Studies on mutational cross-resistance between ciprofloxacin, novobiocin and coumermycin in Escherichia coli and Staphylococcus warneri.
Microbios - 1 Jan 1993
Howard B M, Pinney R J, Smith J T
Abstract excerpt
Nalidixic acid resistant mutants of Escherichia coli KL16 were tested against ciprofloxacin, coumermycin and novobiocin. The mutants gyrA, nalB and nal-24 were more resistant than KL16 to ciprofloxacin, whereas the nal-31 strain was hypersensitive. Only the nalB mutant was more resistant to novobiocin than KL16, but gyrA, nal-31 and nal-24 mutants were more sensitive to coumermycin than KL16. Newly-isolated...
Topics
- Aminocoumarins
- Ciprofloxacin
- Coumarins
- Drug Resistance, Microbial
- Escherichia coli
- Mutation
- Novobiocin
- Phenotype
- Staphylococcus